Phase I Study of P-MUC1C-ALLO1 in Patients with Advanced or Metastatic Solid Tumors, including Pancreatic Cancer
Summary
The purpose of this phase I study is to evaluate the safety and tolerability of P-MUC1C-ALLO1 CAR-T cells with Rimiducid in patients with advanced solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05239143
Study ID: P-MUC1C-ALLO1-001
Trial Phase: Phase I
Trial Sponsor: Poseida Therapeutics, Inc.
Therapies Used in This Trial: Rimiducid